C4 Therapeutics, Inc. CCCC
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026
C4 Therapeutics, Inc. (CCCC) is a healthcare company listed in the US with a market value of about $362M. In the twelve months to September 30, 2026 it had revenue of $32M and net income of -$91M, a net margin of -282.2%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -30%.
About C4 Therapeutics
C4 Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2020. Revenue went from $46M in 2021 to $36M in 2025, a decline of about 5.9% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 70% over three years (dilution for shareholders). It spends 290% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $32M | $36M | $36M | $21M | $31M | $46M | — | — |
| Net income | -$91M | -$105M | -$105M | -$132M | -$128M | -$84M | -$66M | -$34M |
| Free cash flow | -$80M | -$99M | -$65M | -$109M | -$111M | -$88M | -$68M | $54M |
| EPS (diluted) | $-0.63 | $-1.27 | $-1.52 | $-2.67 | $-2.62 | $-1.82 | $-5.83 | $-31.03 |
| Net margin | -282.2% | -292.1% | -296.0% | -638.3% | -412.2% | -183.2% | — | — |
| ROIC | — | -28.7% | -33.5% | -34.6% | -34.4% | -19.0% | -19.7% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $12.50, 353% above the current price; targets range from $6.00 to $30.00; the consensus rating is “Strong buy”; expected EPS is $-0.74 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does C4 Therapeutics pay a dividend?
Not currently.
Is C4 Therapeutics a good stock to buy?
We do not give buy or sell advice. C4 Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.